- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 21 - Expectations for Newly Developing Agents
During this segment, the panelists explore newer therapeutic agents that are now receiving a lot of attention in the healthcare market for the management of cardiovascular health, and discuss which products have the greatest potential when treating cardiometabolic events.
David Calabrese, RPh, MHP, discusses the large number of late-phase agents that are available to treat diabetes and believes that product variety allows clinicians to tailor treatment specifically to the patient.
Additionally, Kenneth L. Schaecher, MD, FACP, CPC, discusses the potential of vaccine therapy and gene therapy, which are currently being studied for the treatment of type 1 diabetes.
Yehuda Handelsman, MD, FACP, FACE, FNLA, concludes the discussion by summarizing the most promising products available to treat other cardiometabolic events such as lipid disorders and obesity.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Impact of Hospital-Physician Integration on Medicare Patient Mix
April 11th 2025This study found no evidence that hospital employment of physicians resulted in physicians treating sicker patients, undercutting claims that hospital-employed physicians serve a higher-acuity patient mix.
Read More
